Skip to main content
Figure 9 | Molecular Pain

Figure 9

From: Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery

Figure 9

Pharmacological specificity of cannabinoid-mediated protection against paclitaxel-induced cold allodynia following drug removal. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-induced protection against paclitaxel-induced cold allodynia was not blocked by either a CB1 (AM251, 3 mg/kg/day s.c.) or CB2 (AM630, 3 mg/kg/day s.c.) antagonist. b. Protective anti-allodynic effects associated with AM1710 (3.2 mg/kg/day s.c.) were mediated via CB2 receptor activation. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle, # P < 0.05, ## P < 0.01, ### P < 0.001 vs. Taxol-Vehicle, + P < 0.05, ++ P < 0.01 vs. Taxol-Agonist + AM630 (3), x P < 0.05, xx P < 0.01, Taxol-Agonist and Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, ⟂ P < 0.05 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3) and Cremophor-Vehicle Ï• P < 0.05, Ï•Ï•Ï• P < 0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3) and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, ^^P < 0.01 Taxol-Agonist and Taxol-Agonist + AM630 (3) vs. Taxol-Vehicle, α P < 0.05 Taxol-Agonist + AM630 (3) and Taxol-Agonist + AM251 (3) vs. Cremophor-Vehicle. All doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 6–8 per group.

Back to article page